SBTX Silverback Therapeutics

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences

Company to Host Conference Call on March 20 at 8:30 a.m. ET

SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Thursday, March 20, 2025, at 8:30 a.m. ET to discuss its fourth quarter and full year 2024 financial results and business highlights. The dial-in information for conference participants may be obtained by .

In addition, ARS Pharma Management will be participating in several upcoming investor conferences:

  • Leerink Partners Global Healthcare Conference: fireside chat on March 10, 2025
  • 37th Annual Roth Conference: investor meetings on March 16-18, 2025

To access the webcast and slides, please visit the page in the Investors & Media section of the Company’s A replay of the webcast will be available for 30 days following the event.

About ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The company is commercializing neffy® 2 mg (trade name EURneffy® in the EU) (previously referred to as ARS-1), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, other allergens, as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit .

Investor Contacts:

Justin Chakma, ARS Pharmaceuticals

Media Contact:

Christy Curran, Sam Brown Inc.



615.414.8668



EN
03/03/2025

Underlying

SBTXSilverback Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Silverback Therapeutics

 PRESS RELEASE
Free
SBTX Silverback Ther...

ARS Pharmaceuticals Announces Conference Call and Webcast for its Firs...

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its first quarter 2025 financial results and business highlights. Dial-in information for conference participants may be ob...

May 5, 2025 1 EN
 PRESS RELEASE
Free
SBTX Silverback Ther...

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and ...

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians Agreement builds on landmark licensing deal between ARS Pharma and ALK-Abelló A/S, which provided ARS Pharma with $145 million upfront and ALK with commercialization rights to neffy in Canada, United Kingdom, European Union and certain other countries outside the United States New partnership expands ARS Pharma’s direct promotional efforts to nearly 20,000 healthcare providers, reaching key pediatrici...

May 2, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 44.17
NEM Newmont Corpora...
MUSA Murphy USA Inc... ... (+24)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

NEM NEWMONT CORPORATION
MUSA MURPHY USA INC.
MOS MOSAIC COMPANY
HNRG HALLADOR ENERGY CO.
HII HUNTINGTON INGALLS INDUSTRIES INC.
GT GOODYEAR TIRE & RUBBER COMPANY
FAST FASTENAL COMPANY
BGS B&G FOODS INC.
CNR. CANADIAN NATIONAL RAILWAY COMPANY
AGX ARGAN INC.
LEU CENTRUS ENERGY CORPORATION
GRPN GROUPON INC.
IPI INTREPID POTASH
SBTX SILVERBACK THERAPEUTICS
SDGR SCHRODINGER
RGC REGENCELL BIOSCIENCE HLDGS LTD
PPTA PERPETUA RESOURCES CORP
MPTI M TRON INDUSTRIES INC
ASPI ASP ISOTOPES INC
ANG ANGLOGOLD ASHANTI LIMITED
AZ A2Z CUST2MATE SOLUTIONS CORP
USAU US GOLD CORP
SLNO SOLENO THERAPEUTICS INC
BKTI BK TECHNOLOGIES CORP
04/14/25 April 14, 2025 1 EN
 PRESS RELEASE
Free
SBTX Silverback Ther...

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financia...

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates $7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing 15 kilograms to < 30 kilograms (33 lbs. to < 66 lbs.), expanding the reach of neffy to approximately 2 million younger, school-aged children at risk of a severe allergic reaction $314.0 million in cash, cash equivalents, and short-term investments at year-end 2024, supporting an inc...

March 20, 2025 1 EN
 PRESS RELEASE
Free
SBTX Silverback Ther...

ARS Pharmaceuticals Announces Conference Call and Webcast for its Four...

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences Company to Host Conference Call on March 20 at 8:30 a.m. ET SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Thursday, March 20, 2025, at 8:30 a.m. ET to discuss its fourth quarter...

March 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch